We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
RAPIVAB (Seqirus Pty Ltd)
Product name
RAPIVAB
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
218 working days (255)
Active ingredients
peramivir
Registration type
NCE/NBE
Indication
RAPIVAB (concentrate for intravenous infusion) is indicated for the treatment of acute influenza infection in adults and children 2 years and older who have been symptomatic for no more than two days.